Agios Pharmaceuticals Stock Price - AGIO

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 52.86 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Agios Pharmaceuticals Inc AGIO NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  1.31 2.54% 52.86 53.27 51.7055 51.75 51.55 00:00:01
Bid Price Ask Price Spread Spread % News
45.70 76.00 30.30 39.87% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
15,458 1,621,424 $ 52.62 $ 85,326,467 880,925 28.36 - 69.64
Last Trade Time Type Quantity Stock Price Currency
17:45:39 priorref 9,875 $ 52.86 USD

Agios Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.61B 68.37M $ -346.03M -6.03 - 67.52M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Agios Pharmaceuticals News

Loading Messages....

Latest AGIO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AGIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week48.7653.2744.3049.011,036,8374.108.41%
1 Month48.0853.2744.3048.84723,6994.789.94%
3 Months31.8253.2728.3640.00952,20121.0466.12%
6 Months47.2353.2728.3639.23742,7595.6311.92%
1 Year55.8669.6428.3645.25619,056-3.00-5.37%
3 Years43.5199.824228.3656.77526,2099.3521.49%
5 Years133.60133.8028.3661.19584,931-80.74-60.43%

Agios Pharmaceuticals Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Your Recent History
Agios Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.